Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: October 30, 2024
Reporting Period: Third quarter ended September 30, 2024
This filing serves as a notification that the company has announced its financial results for the third quarter of 2024. The detailed financial data is contained within the press release attached as Exhibit 99.1, which is not deemed "filed" under Section 18 of the Exchange Act.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being available in the attached press release (Exhibit 99.1) but are not present in the source text provided for this summary.
Material Changes
No material changes versus the prior comparable period can be summarized from the provided text, as the specific financial results and comparative data are not included in the filing excerpt.
Guidance, Outlook, and Risks
The filing text does not provide specific details on guidance, outlook, management commentary, risks, contingencies, or unusual items. It solely confirms the announcement of the Q3 2024 results and references the attached press release for full details.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated October 30, 2024) for actual Q3 2024 revenue, net income, and cash flow figures.
- Verify year-over-year growth rates and margin trends in the attached press release.
- Check for any updated full-year 2024 guidance or forward-looking statements in the press release.
- Confirm the status of key clinical trials or regulatory approvals mentioned in the full announcement.